CRISPR Technology Market

Market Overview

The global CRISPR technology market size was valued at USD 2,251.20 million in 2022. It is projected to reach USD 9512 million by 2031, growing at a CAGR of 26.56% during the forecast period (2023-2031).

CRISPR is a gene-editing tool that permits scientists to manipulate DNA sequences and gene function. It has applications in gene editing. In CRISPR technology, the primary types of products include design tools, plasmid and vector, CAS9 and G-RNA, and delivery system items. CRISPR-Cas9 is a revolutionary technology that permits geneticists and medical researchers to edit parts of the genome by deleting, adding, or modifying DNA sequences. The various applications include genome editing or genetic engineering, genetically modified organisms, agricultural biotechnology, and others.

Multiple industries utilize these applications, including industrial biotech, biological research, agricultural research, therapeutics, and drug discovery. Estimating the size of the CRISPR technology market currently requires four main study initiatives. The market and its peer and parent markets were all the subject of extensive secondary study. The following phase involved conducting primary research to confirm these conclusions, presumptions, and estimates with industry professionals across the value chain.

Highlights

• The enzymes segment is the major contributor to the market by product.
• The biomedical segment is the major contributor to the market by application.
• The pharmaceutical and biotechnology companies’ segment is the major contributor to the market by end-user.
• North America is the major revenue contributor by region.

Market Dynamics

Global CRISPR Technology Market Drivers

Advancement of Government and Private Finance

Government funding for developing CRISPR technology is frequently provided by private companies, government, and individual investigator grants for research projects and programs intended to expand the market. For instance, the Somatic Cell Genome Editing (SCGE) Program at the (NIH) National Institutes of Health has given 24 additional funds to researchers in the United States and Canada in 2019, As per National Center for Advancing Translational Sciences. 

The Bill and Melinda Gates Foundation awarded funding to CRISPR Therapeutics in December 2020 to study in vivo gene editing therapeutics for the treatment of HIV. CRISPR Therapeutics is a biopharmaceutical startup focusing on developing transformational gene-based medicines for acute diseases. The market for CRISPR technology is expected to rise as a result of the industry players' funding to promote CRISPR technology adoption.

Global CRISPR Technology Market Restraint

High Costs of CRISPR

In an article titled "Gene therapy may not be as expensive as people think- challenges in assessing the value of single and short-term therapies," published in the Journal of Managed Care and Specialty Pharmacy in May 2021, the one-time gene therapy Onasemnogene Abeparvovec for spinal muscular atrophy- a rare neuromuscular disease that is typically fatal by the age of two if untreated, has been dubbed the "most expensive medication ever" with a price tag of USD Therefore, over the predicted period, the product's higher prices constrained the market expansion in underdeveloped nations. Due to the concerns above, the high costs of adopting CRISPR may restrain the market's growth throughout the projection period.

Although CRISPR offers tremendous clinical potential for diagnosis and therapy, it is pricey because most gene-editing medicines demand an expensive, highly tailored approach. Additionally, the cost of CRISPR medications for sizable patient populations is probably prohibitive. Only a few businesses are creating CRISPR therapeutics for uncommon diseases, which limits competition. Additionally, because so few individuals can benefit from a specific treatment, revenues from a few doses are necessary, raising the cost of CRISPR therapies.

Global CRISPR Technology Market Opportunities

Rising Demand and CRISPR Adoption

The CRISPR-Cas9 system's expanding use in genome editing and other biotechnological fields is another important element contributing to the market's expansion. Since its involvement in adaptive bacterial immunity was discovered a few years ago, CRISPR has evolved into a potent and widely used genetic tool. Due to its broad range of applications, CRISPR has been widely embraced as a genome engineering platform in various fields, including the pharmaceutical, scientific, agricultural, and biotechnology industries.

According to a study titled "Engineering crops of the future: CRISPR approaches to develop climate-resilient and disease-resistant plants," published in Genome Biology in November 2020, CRISPR has introduced significant agricultural traits into many economically substantial crops, such as heat, cold, and herbicide tolerance; viral, bacterial, and fungal resistance; and increased grain size and weight. As a result of its benefits, CRISPR technology is now widely used in the agriculture sector.

Regional Analysis

North America Dominates the Global Market

The global CRISPR technology market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA. 

North America is the major revenue contributor and is expected to exhibit a CAGR of 21.20% during the forecast period. Due to factors like CRISPR technology innovation, rising product approvals, and expanding research and development processes, the CRISPR market in the United States is predicted to grow significantly throughout the projected period. The first trial in the U.S. to test a CRISPR-made cancer therapy was launched in 2019 at the University of Pennsylvania to determine whether these treatments are safe, according to the National Cancer Institute article "How CRISPR Is Changing Cancer Research and Treatment," published in July 2020. 

Europe is expected to grow at a CAGR of 18.50% during the forecast period. The rising research activities, product releases and approvals, increased clinical trials, and other CRISPR development activities will likely cause the CRISPR market in Germany to expand significantly throughout the study. According to a study published in July 2021 titled "What will the future of CRISPR-Cas 9 in Germany look like in 2035?" CRISPR-Cas9 is expected to be used in medical therapy to treat diseases and extend life during the study period. According to the study, both the religious community and the general public in Germany will be convinced of the benefits of employing gene-editing technology to prevent genetic illnesses and will respond favorably to it. Additionally, it is anticipated that investments in the sector under study will rise. As a result, the analysis indicates a favorable effect on the future market expansion under consideration.

The market in China is predicted to increase due to increasing R&D activities, clinical trial numbers, product approvals, and government and industry-leading strategic initiatives throughout the study. The Chinese government announced proposed regulations allowing the use of genetically modified crops in January 2022, arguing that the country should prioritize developing agricultural research to develop more palatable, pest-resistant, and climate-adaptive crop varieties. The government's efforts to create wheat varieties resistant to powdery mildew have expedited the use of CRISPR gene-editing technology. This should stimulate market growth.

Six nations comprise the Gulf Cooperation Council (GCC): Oman, Saudi Arabia, Kuwait, Bahrain, Qatar, and the United Arab Emirates (UAE). The market is anticipated to increase significantly due to factors including the rising burden of chronic diseases, the growing geriatric population, and the rising number of research and development projects. In Kuwait, 3.4% of the population is 65 years of age, according to the U.N Population Fund's World Population Dashboard's Statistics 2021. The need for CSIPR-based medicines is expected to rise due to increased demand for precise and effective therapeutics, as this age group is more susceptible to chronic diseases like cancer, HIV, and diabetes.

Segmental Analysis

The global CRISPR technology industry is segmented by product, application, and end-user industry.

Based on product, the global market is bifurcated into effect, enzymes, kits and reagents, guide RNA, and others.

The enzymes segment is the major contributor to the market and is estimated to exhibit a CAGR of 19.80% during the forecast period. The Clustered, Regularly Interspaced Short Palindromic Repeat system is getting a lot of attention and is the most widely used method of genome modification. The most straightforward, adaptable, and precise approach to genetic modification at the moment is CRISPR-Cas9. An enzyme known as Cas9 is connected to CRISPR and plays a significant part in this system. It is employed for gene editing and may be used for illness diagnosis. The CRISPR immune systems that shield bacteria and archaea from invasive nucleic acids depend heavily on cash enzymes. Guide RNA (gRNA) can reprogram them to attach and cleave DNA targets.

Due to increased R&D efforts and expanding public awareness of CRISPR technology, the kits and reagents product sector in the market is anticipated to experience substantial growth. The widespread availability of cutting-edge technologies and CRISPR gene editing kits for gene modification investigations meets the increased need for a genome editing solution. CRISPR reagents improve the effectiveness of the CRISPR-mediated gene editing process. For this system, several manufacturers provide a large variety of reagents. For instance, Tocris supplies many chemicals, including AZD 7762 hydrochloride, azidothymidine, BRD 0539, and brefeldin A.

Other products include CRISPR plasmids, blockers, enhancers, primers, and antibodies. The use of other CRISPR products is rising due to researchers' growing interest in creating innovative medicines. Most of the plasmids in CRISPR libraries include several gRNAs for each target gene. Target cells are treated with the pooled library during the screening experiment to produce a population of mutant cells, which are subsequently screened for an exciting phenotype. Additionally, the CRISPR designing tool makes it possible to visualize, optimize, and annotate several gRNA sequences simultaneously.

Based on application, the global market is bifurcated into biomedical, agricultural, industrial, and others.

The biomedical segment is the major contributor to the market and is estimated to exhibit a CAGR of 19.50% during the forecast period. The biomedical sector includes, among other things, functional genomics, epigenetics, disease model research, and genome engineering. The CRISPR/Cas9 system is widely and successfully used for biomedical discoveries in several fields, particularly for detecting mutations and deletions that suggest genetic diseases and sensing nucleic acid-based biomarkers of infectious and non-infectious diseases. 

Food security is badly impacted by the growing worries and shifting weather patterns. Researchers are now continuously researching breakthrough gene-editing technologies to modify staple crops to make them more resistant to the risk linked with climate change, however, to aid in combat these developing problems. By introducing DNA from naturally occurring genetic variations within the crop and not from a different organism that is not compatible with reproduction, CRISPR aids in the development of desirable crop features. This will result in a rise in using CRISPR gene-editing technology to introduce commercially profitable elements in crops. 

Numerous microbial engineering applications can be accomplished with CRISPR, including bacterial strain typing, immunizing cultures, inducing autoimmunity or self-targeted cell death, and engineering or controlling metabolic pathways for better biochemical synthesis. CRISPR also has considerably advanced biotechnology; genome editing has been transformed. However, these technologies are still in development and are not used as widely in bacteria as in eukaryotic organisms. 

Based on the end-user industry, the global market is bifurcated into pharmaceutical companies, biotechnology companies, academics, government research institutes, and others (CROs, etc.)

The pharmaceutical and biotechnology company segment is the major contributor to the market and is estimated to grow at a CAGR of 21.10% during the forecast period. The CRISPR-Cas9 system is being regularly adopted by pharmaceutical and biotechnology companies to develop better biological models for human diseases, which speeds up the discovery and validation of new therapeutic targets. Leading businesses like CRISPR Therapies, Intellia Therapeutics, and Editas Medicine are constantly attempting to make CRISPR-based therapeutics commercially viable. The presence of a sizable clinical pipeline based on CRISPR gene-editing technology and an increase in the number of product releases by significant manufacturers are further factors anticipated to fuel market expansion.

This section lists the institutions and universities engaged in, among other things, cell and gene therapy research. The application of CRISPR technology in academic research and university-run clinical trial programs is extensive and growing. The study of genome editing is expanding along with the study of and interest in medicines. In addition, several businesses are conducting research in collaboration with universities. For instance, Emendo Biotherapeutics and Seattle Children's Research Institute established a research partnership in December 2021 to investigate the extraction of hematopoietic stem cells from patients with (SCN) severe congenital neutropenia using CRISPR-based therapies.

Recent Developments

• October 2022- A robot bacteriophage of the second generation was created by iNtron Biotechnology. In addition to the previously revealed customized CRISPR/Cas system for bacteriophage engineering advancement, the random transposon mutagenesis technique is applied to the bacteriophage genome.
• September 2022- Vertex and CRISPR Therapeutics were discussing to end the offer by the end of Q1 2023 after completing a discussion with the U.S. Food and Drug Administration for the filing of the exa-cel in November 2022.